Caricamento...
Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer
Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR-sensitizing mutations or the T790M mutation. However, the potential therapeutic effect of osimertinib combined with...
Salvato in:
| Pubblicato in: | Oncol Rep |
|---|---|
| Autori principali: | , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
D.A. Spandidos
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6278463/ https://ncbi.nlm.nih.gov/pubmed/30365094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2018.6803 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|